Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Mysthera Therapeutics logo — Multilineage immune modulation. The next chapter in autoimm...

Mysthera Therapeutics

Multilineage immune modulation. The next chapter in autoimmune diseases.

Founded 2023 Switzerland Basel, Switzerland 3 employees Seed Total: $3.50M Health Care, Health and Wellness

General Information

Company Name Mysthera Therapeutics
Founded Year 2023
Location Switzerland Basel, Switzerland +1
Employees 3
Industries Health Care, Health and Wellness
Funding Stage Seed
Social

Get notified when Mysthera Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Mysthera Therapeutics

Mysthera Therapeutics is a preclinical stage biotech start-up pioneering multilineage immune modulation for autoimmune diseases. Founded in 2023 in Switzerland by Forty51 Ventures, it received a $3.50M Seed Round investment on 21 August 2023. Their unique approach focuses on developing first-in-class, oral therapeutics targeting autoimmune diseases such as glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. Mysthera is the first to develop PIM kinase inhibitors for multi-lineage immune cell-driven autoimmune diseases. With an expert team at the helm, the company operates in Europe’s pharma/biotech hub, Basel, and aims to transform patient lives through innovative treatments.

Taxonomy: biotech start-up, immunotherapy, autoimmune diseases, PIM kinase inhibitors, multi-lineage immune modulation, glomerulonephritis, rheumatoid arthritis, inflammatory bowel disease, Basel, Europe, pharma, therapeutics, preclinical stage, immune cell, Forty51 Ventures

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 1
Investor
21 Aug 2023

Mysthera Therapeutics Alternatives & Competitors

Mysthera Therapeutics vs
Nuvig Therapeutics
Nuvig Therapeutics

Pioneering Autoimmune Therapies for a New Standard of Care.

Mysthera Therapeutics vs
Kanaph Therapeutics
Kanaph Therapeutics Korea South

We are the leader of next generation immuno-oncology and autoimmune diseases.

Series B
16 employees
Biotechnology, Pharmaceutical
Mysthera Therapeutics vs
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. United States

Orchestrating the Immune System

Series A
36 employees
Biotechnology

FAQ About Mysthera Therapeutics

Multilineage immune modulation. The next chapter in autoimmune diseases.
Mysthera Therapeutics was founded in 2023.
Mysthera Therapeutics is headquartered in Basel, Switzerland.
Mysthera Therapeutics operates in the following industries: Health Care, Health and Wellness.
Mysthera Therapeutics has approximately 3 employees.
Mysthera Therapeutics has completed 1 funding round, raising a total of $3.50M. The latest funding stage is Seed.
Top alternatives and competitors to Mysthera Therapeutics include Nuvig Therapeutics, Kanaph Therapeutics, Mozart Therapeutics, Inc., Cogen Therapeutics, Valocor Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mysthera Therapeutics and Nuvig Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Mysthera Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes